Full Press Release Details
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference.
BIIB
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Key Takeaway: Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Price reaction · baseline $183.47 (2024-10-29 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
-1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis